Antares Pharma Inc. said today that it received a noncompliance notice Tuesday from the New York Stock Exchange's Amex exchange.

The Ewing, N.J.-based company, which focuses on drug-delivery technology, said it was told that its stockholders' equity of less than $6 million and losses, including net losses in its five most recent years, had warranted the delisting warning.

Antares, which makes a drug to control hot flashes associated with menopause, said it would seek to retain its listing and submit a plan by the July 1 deadline.

The company would have 18 months (until Dec. 1, 2010) to implement the plan.

Late this morning, shares were trading at 69 cents, up 9 cents (14.98 percent); they have ranged from 29 cents to 90 cents in the last 52 weeks.